Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting
Objective: Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with ac...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-07-01
|
| Series: | Jornal de Pediatria |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0021755715000637 |
| _version_ | 1817988095456313344 |
|---|---|
| author | Ener Cagri Dinleyici Nazan Dalgic Sirin Guven Ozge Metin Olcay Yasa Zafer Kurugol Ozden Turel Gonul Tanir Ahmet Sami Yazar Vefik Arica Mesut Sancar Adem Karbuz Makbule Eren Metehan Ozen Ates Kara Yvan Vandenplas |
| author_facet | Ener Cagri Dinleyici Nazan Dalgic Sirin Guven Ozge Metin Olcay Yasa Zafer Kurugol Ozden Turel Gonul Tanir Ahmet Sami Yazar Vefik Arica Mesut Sancar Adem Karbuz Makbule Eren Metehan Ozen Ates Kara Yvan Vandenplas |
| author_sort | Ener Cagri Dinleyici |
| collection | DOAJ |
| description | Objective: Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea. Methods: This was a multicenter, randomized, single-blinded, case control clinical trial in children with acute watery diarrhea. A total of 64 children who presented at outpatient clinics were enrolled. The probiotic group received 1 × 108 CFU L. reuteri DSM 17938 for five days in addition to oral rehydration solution (ORS) and the second group was treated with ORS only. The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the number of children with diarrhea at each day of the five days of intervention. Adverse events were also recorded. Results: The mean duration of diarrhea was significantly reduced in the L. reuteri group compared to the control group (approximately 15 h, 60.4 ± 24.5 h [95% CI: 51.0–69.7 h] vs. 74.3 ± 15.3 h [95% CI: 68.7–79.9 h], p < 0.05). The percentage of children with diarrhea was lower in the L. reuteri group (13/29; 44.8%) after 48 h than the control group (27/31; 87%; RR: 0.51; 95% CI: 0.34–0.79, p < 0.01). From the 72nd hour of intervention onwards, there was no difference between the two groups in the percentage of children with diarrhea. No adverse effects related to L. reuteri were noted. Conclusion: L. reuteri DSM 17938 is effective, safe, and well-tolerated in outpatient children with acute infectious diarrhea. Resumo: Objetivo: Dois ensaios clínicos randomizados controlados demonstraram que o Lactobacillus (L) reuteri DSM 17938 reduz a duração de diarreia em crianças hospitalizadas devido a diarreia infecciosa aguda. Este é o primeiro ensaio que avalia a eficácia do L. reuteri DSM 17938 em crianças com diarreia infecciosa aguda no ambulatório. Métodos: Este foi um ensaio clínico multicêntrico, randomizado, único cego, com grupos paralelos e controlado em crianças com diarreia aguda. Um total de 64 crianças internadas na clínica ambulatorial foram inscritas. O grupo probiótico recebeu 1 × 108 CFU L. reuteri DSM 17938 por cinco dias, além de uma solução de reidratação oral (SRO), e o segundo grupo foi tratado apenas com SRO. O desfecho principal foi a duração da diarreia (em horas). O desfecho secundário foi o número de crianças com diarreia em cada um dos cinco dias da intervenção. Os eventos adversos também foram registrados. Resultados: A duração média da diarreia foi significativamente reduzida no grupo L. reuteri em comparação ao grupo de controle (aproximadamente 15 horas; 60,4 ± 24,5 horas [51, 0–69, 7 horas, IC de 95%] em comparação a 74,3 ± 15,3 horas [68, 7–79, 9 horas, IC de 95%], p < 0,05). O percentual de crianças com diarreia foi menor no grupo L. reuteri (13/29; 44,8%) após 48 horas que no grupo de controle (27/31; 87%) (RR: 0,51; 0, 34–0, 79; IC de 95%, <0,01). A partir da 72ª hora de intervenção, não havia nenhuma diferença entre os dois grupos no percentual de crianças com diarreia. Nenhum efeito adverso com relação ao L. reuteri foi observado. Conclusão: O L. reuteri DSM 17938 é eficaz, seguro e bem tolerado por crianças com diarreia infecciosa aguda no ambulatório. Keywords: Lactobacillus reuteri DSM 17938, Diarrhea, Children, Probiotic, Ambulatory care, Palavras-chave: Lactobacillus reuteri DSM 17938, Diarreia, Crianças, Probióticos, Cuidado ambulatorial |
| first_indexed | 2024-04-14T00:30:01Z |
| format | Article |
| id | doaj.art-37e89b61fd0c43e7a58ea8f3ca34dcf9 |
| institution | Directory Open Access Journal |
| issn | 0021-7557 |
| language | English |
| last_indexed | 2024-04-14T00:30:01Z |
| publishDate | 2015-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Jornal de Pediatria |
| spelling | doaj.art-37e89b61fd0c43e7a58ea8f3ca34dcf92022-12-22T02:22:34ZengElsevierJornal de Pediatria0021-75572015-07-01914392396Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient settingEner Cagri Dinleyici0Nazan Dalgic1Sirin Guven2Ozge Metin3Olcay Yasa4Zafer Kurugol5Ozden Turel6Gonul Tanir7Ahmet Sami Yazar8Vefik Arica9Mesut Sancar10Adem Karbuz11Makbule Eren12Metehan Ozen13Ates Kara14Yvan Vandenplas15Faculty of Medicine, Department of Pediatrics, Pediatric Intensive Care and Infectious Disease Unit, Eskisehir Osmangazi University, Eskisehir, Turkey; Corresponding author.Division of Pediatric Infectious Diseases, Sisli Etfal Training and Research Hospital, Istanbul, TurkeyDepartment of Pediatrics, Umraniye Education & Research Hospital, Istanbul, TurkeyPediatric Infectious Disease Unit, Dr. Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Ankara, TurkeyDepartment of Pediatrics, Goztepe Training and Research Hospital, SB Istanbul Medeniyet University, Istanbul, TurkeyDepartment of Pediatrics, Faculty of Medicine, Ege University, İzmir, TurkeyDepartment of Pediatric Infectious Disease Unit, Faculty of Medicine, Bezmialem Vakif University, Istanbul, TurkeyPediatric Infectious Disease Unit, Dr. Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Ankara, TurkeyDepartment of Pediatrics, Umraniye Education & Research Hospital, Istanbul, TurkeyDepartment of Pediatrics, Okmeydani Education and Research Hospital, Istanbul, TurkeyFaculty of Pharmacy, Clinical Pharmacy Department, Marmara University, Istanbul, TurkeyDepartment of Pediatrics, Okmeydani Education and Research Hospital, Istanbul, TurkeyFaculty of Medicine, Pediatric Infectious Disease Unit, Hacettepe University, Ankara, TurkeyDepartment of Pediatrics, Okmeydani Education and Research Hospital, Istanbul, TurkeyFaculty of Pharmacy, Clinical Pharmacy Department, Marmara University, Istanbul, TurkeyDepartment of Pediatrics, UZ Brussel, Vrije Universiteit Brussel, Brussels, BelgiumObjective: Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea. Methods: This was a multicenter, randomized, single-blinded, case control clinical trial in children with acute watery diarrhea. A total of 64 children who presented at outpatient clinics were enrolled. The probiotic group received 1 × 108 CFU L. reuteri DSM 17938 for five days in addition to oral rehydration solution (ORS) and the second group was treated with ORS only. The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the number of children with diarrhea at each day of the five days of intervention. Adverse events were also recorded. Results: The mean duration of diarrhea was significantly reduced in the L. reuteri group compared to the control group (approximately 15 h, 60.4 ± 24.5 h [95% CI: 51.0–69.7 h] vs. 74.3 ± 15.3 h [95% CI: 68.7–79.9 h], p < 0.05). The percentage of children with diarrhea was lower in the L. reuteri group (13/29; 44.8%) after 48 h than the control group (27/31; 87%; RR: 0.51; 95% CI: 0.34–0.79, p < 0.01). From the 72nd hour of intervention onwards, there was no difference between the two groups in the percentage of children with diarrhea. No adverse effects related to L. reuteri were noted. Conclusion: L. reuteri DSM 17938 is effective, safe, and well-tolerated in outpatient children with acute infectious diarrhea. Resumo: Objetivo: Dois ensaios clínicos randomizados controlados demonstraram que o Lactobacillus (L) reuteri DSM 17938 reduz a duração de diarreia em crianças hospitalizadas devido a diarreia infecciosa aguda. Este é o primeiro ensaio que avalia a eficácia do L. reuteri DSM 17938 em crianças com diarreia infecciosa aguda no ambulatório. Métodos: Este foi um ensaio clínico multicêntrico, randomizado, único cego, com grupos paralelos e controlado em crianças com diarreia aguda. Um total de 64 crianças internadas na clínica ambulatorial foram inscritas. O grupo probiótico recebeu 1 × 108 CFU L. reuteri DSM 17938 por cinco dias, além de uma solução de reidratação oral (SRO), e o segundo grupo foi tratado apenas com SRO. O desfecho principal foi a duração da diarreia (em horas). O desfecho secundário foi o número de crianças com diarreia em cada um dos cinco dias da intervenção. Os eventos adversos também foram registrados. Resultados: A duração média da diarreia foi significativamente reduzida no grupo L. reuteri em comparação ao grupo de controle (aproximadamente 15 horas; 60,4 ± 24,5 horas [51, 0–69, 7 horas, IC de 95%] em comparação a 74,3 ± 15,3 horas [68, 7–79, 9 horas, IC de 95%], p < 0,05). O percentual de crianças com diarreia foi menor no grupo L. reuteri (13/29; 44,8%) após 48 horas que no grupo de controle (27/31; 87%) (RR: 0,51; 0, 34–0, 79; IC de 95%, <0,01). A partir da 72ª hora de intervenção, não havia nenhuma diferença entre os dois grupos no percentual de crianças com diarreia. Nenhum efeito adverso com relação ao L. reuteri foi observado. Conclusão: O L. reuteri DSM 17938 é eficaz, seguro e bem tolerado por crianças com diarreia infecciosa aguda no ambulatório. Keywords: Lactobacillus reuteri DSM 17938, Diarrhea, Children, Probiotic, Ambulatory care, Palavras-chave: Lactobacillus reuteri DSM 17938, Diarreia, Crianças, Probióticos, Cuidado ambulatorialhttp://www.sciencedirect.com/science/article/pii/S0021755715000637 |
| spellingShingle | Ener Cagri Dinleyici Nazan Dalgic Sirin Guven Ozge Metin Olcay Yasa Zafer Kurugol Ozden Turel Gonul Tanir Ahmet Sami Yazar Vefik Arica Mesut Sancar Adem Karbuz Makbule Eren Metehan Ozen Ates Kara Yvan Vandenplas Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting Jornal de Pediatria |
| title | Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| title_full | Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| title_fullStr | Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| title_full_unstemmed | Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| title_short | Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| title_sort | lactobacillus reuteri dsm 17938 shortens acute infectious diarrhea in a pediatric outpatient setting |
| url | http://www.sciencedirect.com/science/article/pii/S0021755715000637 |
| work_keys_str_mv | AT enercagridinleyici lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT nazandalgic lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT siringuven lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT ozgemetin lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT olcayyasa lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT zaferkurugol lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT ozdenturel lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT gonultanir lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT ahmetsamiyazar lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT vefikarica lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT mesutsancar lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT ademkarbuz lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT makbuleeren lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT metehanozen lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT ateskara lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting AT yvanvandenplas lactobacillusreuteridsm17938shortensacuteinfectiousdiarrheainapediatricoutpatientsetting |